Evidence map›Paper›PMID 26933876›Full record

ArticleJournal of addiction medicine

Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.

B Levi Bolin, William W Stoops, Jeremy P Sites, Craig R Rush

Open access · greenAbstract readControlled Clinical Trial
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Effect of amphetamines on blood pressure.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

B Levi BolinDepartment of Behavioral Science (BLB, WWS, CRR), University of Kentucky College of Medicine, 140 Medical Behavioral Science Building, Lexington, KY; Department of Psychology (WWS, CRR), University of Kentucky College of Arts and Sciences, 110 Kastle Hall, Lexington, KY; Department of Psychiatry (WWS, CRR), University of Kentucky College of Medicine, 3470 Blazer Parkway, Lexington, KY; and University of Kentucky College of Medicine (JPS), 138 Leader Avenue, Lexington, KY.
William W Stoops
Jeremy P Sites
Craig R Rush
Office of the Director · USUniversity of Kentucky · US

Funding

Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab StudiesR01DA025032 · NIDA · UNIVERSITY OF KENTUCKY · PI RUSH, CRAIG R · 2009 to 2013
$1.8M
NIDA NIH HHS R01 DA025032NIDA NIH HHS T32 DA035200
6 · The paper itself

Abstract

objectivesPhendimetrazine is a prodrug for the monoamine releaser phenmetrazine-a drug with known abuse potential. Preclinical studies suggest that phendimetrazine has limited abuse potential and may have promise as an agonist-like replacement therapy for cocaine dependence. This study evaluated the abuse potential of phendimetrazine in humans.

methodsNine cocaine-dependent individuals (N = 9) were enrolled to investigate the abuse potential of phendimetrazine and d-amphetamine, using a double-blind, placebo-controlled, within-subject design. Subjective and cardiovascular effects of oral phendimetrazine (35, 70, and 105 mg), d-amphetamine (10, 20, and 30 mg), and placebo were assessed in quasi-random order across 8 sessions lasting for approximately 8 hours each.

resultsd-Amphetamine (20 and 30 mg) significantly increased cardiovascular measures in a time and dose-related manner, but phendimetrazine did not systematically alter cardiovascular measures. Although d-amphetamine and phendimetrazine significantly increased ratings indicative of abuse potential (eg, drug liking) and stimulant-like effects relative to placebo, these increases were generally small in magnitude, with phendimetrazine producing significant effects on fewer abuse-related measures and at fewer time points than d-amphetamine.

conclusionsThese preliminary findings suggest that oral phendimetrazine and d-amphetamine may have limited abuse potential in cocaine-dependent individuals. These findings collectively emphasize that the clinical utility of medications to treat cocaine-use disorders should be weighed carefully against their potential for abuse and diversion, with careful attention paid to evaluating abuse potential in a clinically relevant population of interest. Future studies are needed to further elucidate the potential utility of phendimetrazine as an agonist-like replacement therapy for cocaine dependence.

Indexed as

Prescription Drug MisuseAdultCentral Nervous System StimulantsCocaine-Related DisordersDextroamphetamineDouble-Blind MethodFemaleHumansMaleMiddle AgedMorpholinesTreatment OutcomeCentral Nervous System StimulantsDextroamphetamineMorpholinesphendimetrazine

Identifiers

PMID26933876
PMCPMC4880531
OpenAlexW2332998234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.